Valuation: Access Pharmaceuticals, Inc.

Market Cap 300M 267M 249M 227M 428M 28.9B 434M 3.02B 1.17B 14.72B 1.13B 1.1B 47.28B P/E 2026 *
-5.09x
P/E 2027 * -25x
Enterprise Value 300M 267M 249M 227M 428M 28.9B 434M 3.02B 1.17B 14.72B 1.13B 1.1B 47.28B EV / Sales 2026 *
5.7x
EV / Sales 2027 * 2.6x
Free-Float
84.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 2021-10-14
Director of Finance/CFO 42 2022-03-13
Chief Tech/Sci/R&D Officer - 2025-10-19
Director TitleAgeSince
Director/Board Member 58 2006-02-28
Director/Board Member 64 2021-03-24
Director/Board Member 63 2021-04-18
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-0.10%+50.70%+114.07% 1,031B
-2.30%-3.90%+39.50%+66.07% 638B
-0.63%-1.94%+12.26%+74.38% 462B
-1.03%-2.88%+71.35%+39.69% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.29%+44.32%+51.54% 228B
-1.04%-2.56%+32.88%+96.82% 185B
Average -1.29%-0.36%+34.53%+57.34% 418.21B
Weighted average by Cap. -1.02%-0.35%+38.05%+69.18%

Financials

2026 *2027 *
Net sales 52.63M 46.75M 43.72M 39.84M 75M 5.07B 76.03M 529M 205M 2.58B 198M 193M 8.29B 116M 103M 96.04M 87.52M 165M 11.13B 167M 1.16B 450M 5.67B 434M 425M 18.21B
Net income -56.16M -49.88M -46.65M -42.51M -80.03M -5.41B -81.13M -564M -218M -2.75B -211M -206M -8.85B -11.39M -10.11M -9.46M -8.62M -16.23M -1.1B -16.45M -114M -44.29M -558M -42.75M -41.82M -1.79B
Net Debt - -
Logo Access Pharmaceuticals, Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-